Anastasiou, Ioanna A. published the artcileIn vitro data of current therapies for SARS-CoV-2, Quality Control of 55981-09-4, the main research area is review therapy SARS CoV 2; ACE2 receptor; SARS-CoV-2 (COVID-19); VeroE6 Cells; in vitro studies; therapies; vaccines.
Background: In Dec. 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in the Wuhan region and then spread worldwide. Due to a lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find a therapeutic solution Objectives: The aim of this study was to summarize in vitro data of current agents used for the management of SARS-CoV-2 all over the world. Methods: A literature search of articles from Jan. 2000 until Apr. 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2. Results: Although in vitro studies are scarce, data regarding chloroquine, hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine, and emetine seem promising. Conclusion: Scientists all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat.
Current Medicinal Chemistry published new progress about Allium sativum. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Quality Control of 55981-09-4.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics